Ontario joins Quebec, Alberta and Saskatchewan to fund gene-based treatment for previously untreatable genetic retinal conditions1 Luxturna® is the first and only pharmacological treatment for an inherited retinal disease designed to help improve functional vision in patients… Read More
Arrival of PrBYOOVIZ™ provides new, sustainable treatment option for Canadians with serious eye disorders that can lead to irreversible vision loss BYOOVIZ brings biosimilar science and the recognized efficacy of reference… Read More
MISSISSAUGA, ON — AstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint… Read More
VANCOUVER, BC — Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the publication of a study in Nature Biotechnology describing… Read More
MONTREAL, QC — The members of IRICoR’s Board of Directors are proud today to announce the appointment of Elizabeth Douville, Ph.D., ICD.D, to the position of President and Chief Executive… Read More
